LGALS1 and cancer: Accumulating evidence suggests that dysregulated expression of Gal-1, -3, and -9 in various types of cancers contributes to the immunosuppressive TME via their binding to T cell surface glycosylated receptors that modulate effector function and, in some cases, induce apoptosis [78].